Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

4상 조기 종료 NCT03471117

요약

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.

Muscle Sympathetic Nerve Activity (MSNA)

1 month · MSNA burst frequency (bursts/min)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
• Improving Hypertension Medication Adherence for Older Adults — University of Arizona
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
• SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca

전체 임상